Amrutanjan Health Care Limited (AMRUTANJAN) share price
₹490.95 on NSE as of 2026-09-11. -0.47% on the day. market cap ₹1,419 Cr. P/E 26.3. 52-week range ₹488.25 to ₹768.35. Healthcare.
What the company does
FMCG) FMCG Diversified FMCG Diversified FMCG AHCL was established in 1893 by K. Nageswara Rao Pantulu as a patent medicine business with the launch of its flagship product, Amrutanjan Pain Balm. Headquartered in Chennai, the company primarily manufactures OTC ayurvedic healthcare products focused on pain management and congestion relief. Over the years, it has expanded beyond its flagship balms into a diversifie d portfolio spanning pain management, congestion relief, beverages, and women’s hygiene. AHCL operates two OTC product manufacturing units, in Kancheepuram District, Tamil Nadu, and Hyderabad, and a beverages facility in Tiruvallur District, Tamil Nadu. The company has established a cGMP-certified production line within its Kancheepuram unit for manufacture of OTC monograph topical application products. In June 2026, the company also commenced operations at its sanitary napkin manufacturing plant in Hyderabad. AHCL also operates an Advanced Pain Management Centre in Chennai, providing non-surgical pain management services.
Filed by CARE Ratings, page 4.
Amrutanjan Health Care Q1 FY27: Sales Up 9.5% to ₹103 Cr, a ₹150 Cr Napkin Plant, and a 133-Year-Old Balm Having a Quiet Quarter
At a glance
Revenue from operations for the quarter ended 30 June 2026 was ₹102.97 crore, up 9.48% from ₹94.05 crore a year earlier. Operating profit was ₹6.24 crore against ₹8.44 crore. Profit after tax was ₹4.37 crore against ₹8.31 crore. EPS came in at ₹1.51.
The gap between "sales up" and "profit down" has a documented cause and a receipt attached to it. The company disclosed an exceptional item of ₹202.75 lakh in the quarter — the last instalment of a lease-rent dispute that has been travelling through the Madras High Court since 2005-06, which is long enough for a legal matter to grow up, finish school and get a job. Profit before exceptional item and tax was ₹8.10 crore; profit before tax after it was ₹6.07 crore.
Elsewhere in the quarter: the company commissioned a ₹150 crore greenfield sanitary napkin plant in Telangana, its fifth manufacturing facility, with two automated lines imported from Japan. Comfy's contribution to overall sales moved to 33% from 29% a year ago. Razors and antiseptic plasters — categories the company did not sell eighteen months ago — contributed 4% of Q1 sales.
On 11 August the board approved the results, scheduled the 89th AGM for 23 September 2026, and fixed 11 September as the record date for a final dividend of ₹2.90 per share. Eighty-nine AGMs is the kind of number that makes a company's paperwork older than most of its competitors' entire existence.
The quarter's operating profit margin was 6.06%.
Introduction
Amrutanjan Health Care Limited was established in 1893 by K. Nageswara Rao Pantulu as a patent medicine business, launched around a single product: the Amrutanjan Pain Balm. Per CARE Ratings, the company's legacy spans 133 years, and the current Chairman and Managing Director, S. Sambhu Prasad, represents the third generation of promoter leadership. The registered office is on Luz Church Road, Mylapore, Chennai — an address that has presumably watched several eras of Indian commerce walk past its gate.
For the better part of a century the story was straightforward: a balm, a jar, a smell that every Indian nose can identify blindfolded. The diversification is comparatively recent. Per CARE's report, the company entered women's hygiene in 2011 with traded sanitary napkins under the brand "Comfy", and in the same year acquired Fruitnik, a fruit juice and non-carbonated soft drinks brand, subsequently repositioned toward juices and electrolyte-infused beverages.
The most recent additions arrived in Q4 FY26, when the company launched men's razors under "Smoothe", women's razors under Comfy, Amrutanjan Plastry antiseptic plasters, an Advanced Ortho Pain Relief Oil and a Relief Nasal Spray — five product lines in one quarter, from a company that spent its first hundred years selling essentially one thing.
FY26 closed with sales of ₹502.55 crore and net profit of ₹57.92 crore. Then the calendar turned and Q1 FY27 arrived carrying a court order, a new factory and a razor business.
Per the investor presentation, the ₹150 crore Telangana plant spans 10 acres with 1.4 lakh sq. ft. of built-up area, and per CARE's report, women's hygiene manufacturing was previously outsourced. On 18 October 2025 the company disclosed a GST appellate order reversing input tax credit, with a demand of ₹1,17,66,455 plus interest and penalty, and stated it would appeal.
Business model
Four segments, per the results filing: OTC Products, Women's Hygiene & Personal Care, Beverages, and Others — the last of which is the Advanced Pain Management Centre in Chennai, a clinic run by a balm company, because if you have spent 133 years thinking about aches you may as well open a room about it.
Q1 FY27 segment revenue: OTC Products ₹57.26 crore, Women's Hygiene & Personal Care ₹36.36 crore, Beverages ₹8.64 crore, Others ₹0.72 crore.
The OTC business is the brand everyone knows. Pain management under Amrutanjan, congestion relief under Relief. Per the presentation, Q1 gross sales were ₹57.0 crore in pain management and ₹2.3 crore in congestion. Within pain, the SKU-level detail reads like a size chart with opinions: the 1ml sachet grew 20%, the head roll-on grew 1%, and the 8ml pack declined 23%. Management notes that per IQVIA data, category volume growth in Q1 was -3.4% against +6.6% in the corresponding quarter of FY26, and that for the first time the value share of analgesic pills surpassed the rubs category. A hundred and thirty-three years of rubbing things on your forehead, quietly being out-marketed by a tablet.
Women's hygiene is Comfy — sanitary napkins, now made in-house at the Telangana plant, plus women's razors. Gross sales were ₹36.9 crore in the quarter, with Comfy XL up 43% and the 18-unit value pack up 24%. India's sanitary napkin market apparently rewards the large sizes and the bulk packs, which is the least surprising sentence in this entry.
Beverages covers Electro+ (WHO ORS) and Enerlyte, plus the Fruitnik juice line. Rehydration gross sales were ₹9.3 crore. Per management, the category is transitioning to a new FSSAI regime restricting how electrolyte drinks may be marketed, and the beverage category posted 11% growth in the period.
Distribution: per CARE's report, as of 31 March 2025 the company had 1,656 distributors and product presence across 1.11 million outlets. Eleven lakh shops carrying a small yellow jar is not a business, it is an ambient national condition. Southern states (Tamil Nadu, Karnataka, Andhra Pradesh) and eastern states (Odisha, West Bengal, Assam) together accounted for roughly 60% of FY26 revenue, and exports contributed about 2%.
Quarterly results, balance sheet, cash flow, ratios, shareholding and the filings themselves are on the full page for Amrutanjan Health Care Limited.
Companies in the same industry as Amrutanjan Health Care Limited
Pharmaceuticals